CDC committee votes to resume Johnson & Johnson COVID-19 vaccine despite possible blood clot link

A Centers for Disease Control and Prevention (CDC) advisory committee is recommending that the Johnson & Johnson COVID-19 vaccine resume rollout, but include new language on the product’s emergency use authorization (EUA) warning remote risks of serious blood clots.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button